Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
5.64
+0.94 (20.00%)
At close: Mar 28, 2025, 4:00 PM
5.39
-0.25 (-4.43%)
After-hours: Mar 28, 2025, 7:45 PM EDT
Alumis Employees
As of December 31, 2024, Alumis had 170 total employees, including 168 full-time and 2 part-time employees. The number of employees increased by 61 or 55.96% compared to the previous year.
Employees
170
Change (1Y)
61
Growth (1Y)
55.96%
Revenue / Employee
n/a
Profits / Employee
-$1,730,782
Market Cap
306.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170 | 61 | 55.96% |
| Dec 31, 2023 | 109 | - | - |
ALMS News
- 3 days ago - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan - GlobeNewsWire
- 9 days ago - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 18 days ago - Alumis to Present at Leerink's 2025 Global Healthcare Conference - GlobeNewsWire
- 20 days ago - Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis - GlobeNewsWire
- 24 days ago - Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - GlobeNewsWire
- 24 days ago - ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - GlobeNewsWire
- 4 weeks ago - Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout - GlobeNewsWire
- 4 weeks ago - Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases - GlobeNewsWire